TARPEYO (Nefecon)

About Calliditas Therapeutics

Calliditas Therapeutics is a Swedish biopharma focused on identifying, developing, and commercializing novel treatments for orphan indications, with an initial focus on renal and hepatic diseases. Its major achievement is the full FDA approval and commercialization of TARPEYO® for IgA nephropathy (IgAN), establishing a new standard of care. The company employs a capital-efficient strategy, directly commercializing in the U.S. while leveraging strategic partnerships with Everest Medicines, STADA, and Viatris for global expansion. Its pipeline is anchored by a second platform, setanaxib, a NOX inhibitor in development for fibrotic and oncological indications.

Therapeutic Areas

Other IgA Nephropathy (IgAN) Drugs